Australia markets open in 9 hours 54 minutes

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
137.26-0.24 (-0.17%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 510.78B
Enterprise value 39.5B
Trailing P/E N/A
Forward P/E 1-32.68
PEG ratio (5-yr expected) 1119.85
Price/sales (ttm)23.94
Price/book (mrq)10.32
Enterprise value/revenue 321.09
Enterprise value/EBITDA 6-16.72

Trading information

Stock price history

Beta (5Y monthly) 1.81
52-week change 364.32%
S&P500 52-week change 314.13%
52-week high 3175.00
52-week low 378.06
50-day moving average 3140.19
200-day moving average 3144.91

Share statistics

Avg vol (3-month) 3666.02k
Avg vol (10-day) 3384.96k
Shares outstanding 578.51M
Float 74.71M
% held by insiders 14.82%
% held by institutions 195.52%
Shares short (29 Sep 2020) 49.13M
Short ratio (29 Sep 2020) 412.18
Short % of float (29 Sep 2020) 413.75%
Short % of shares outstanding (29 Sep 2020) 411.62%
Shares short (prior month 30 Aug 2020) 49.46M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 311 Jul 2012

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2019
Most-recent quarter (mrq)29 Jun 2020

Profitability

Profit margin -117.80%
Operating margin (ttm)-133.27%

Management effectiveness

Return on assets (ttm)-16.19%
Return on equity (ttm)-49.52%

Income statement

Revenue (ttm)450.19M
Revenue per share (ttm)5.94
Quarterly revenue growth (yoy)45.10%
Gross profit (ttm)-236.46M
EBITDA -568M
Net income avi to common (ttm)-530.34M
Diluted EPS (ttm)-7.00
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.06B
Total cash per share (mrq)26.26
Total debt (mrq)781.39M
Total debt/equity (mrq)74.93
Current ratio (mrq)6.93
Book value per share (mrq)13.30

Cash flow statement

Operating cash flow (ttm)288.96M
Levered free cash flow (ttm)-131.42M